Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Fecal microbiota transplantation94 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00181 | 35195774 | Arch Microbiol | A review on the effect of gut microbiota on metabolic diseases. | 2022 | Details |
| A00384 | 35108315 | PLoS One | Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. | 2022 | Details |
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | 2021 | Details |
| A00955 | 34920070 | Int J Biol Macromol | MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila. | 2021 | Details |
| A01187 | 34835981 | Nutrients | Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice. | 2021 | Details |
| A01368 | 34773257 | Hepatology | A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. | 2021 | Details |
| A01474 | 34734433 | J Gastroenterol Hepatol | New perspective on fecal microbiota transplantation in liver diseases. | 2022 | Details |
| A01475 | 34734369 | J Gastrointest Surg | The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. | 2021 | Details |
| A01838 | 34598315 | Immun Inflamm Dis | Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. | 2021 | Details |
| A01945 | 34557498 | Front Med (Lausanne) | Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. | 2021 | Details |
| A02176 | 34473644 | Aging (Albany NY) | Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. | 2021 | Details |
| A02186 | 34469716 | Cell Rep | Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. | 2021 | Details |
| A02259 | 34444932 | Nutrients | The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A02359 | 34403877 | Phytomedicine | A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. | 2021 | Details |
| A02865 | 34212214 | Inflamm Res | Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. | 2021 | Details |
| A02892 | 34204274 | Int J Mol Sci | Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. | 2021 | Details |
| A03134 | 34118321 | Gastroenterol Hepatol | Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. | 2021 | Details |
| A03453 | 33994854 | Int J Biol Sci | Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. | 2021 | Details |
| A03556 | 33957682 | Semin Liver Dis | New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03731 | 33887125 | United European Gastroenterol J | Gut fermentation syndrome: A systematic review of case reports. | 2021 | Details |
| A03771 | 33869077 | Front Cell Infect Microbiol | The Role of Gut Microbiota in Duodenal-Jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats. | 2021 | Details |
| A04087 | 33765728 | Clin Endosc | Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection. | 2021 | Details |
| A04200 | 33718398 | Front Med (Lausanne) | Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. | 2021 | Details |
| A04352 | 33652261 | Biomed Pharmacother | Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury. | 2021 | Details |
| A04456 | 33609303 | Hepatology | Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. | 2021 | Details |
| A04617 | 33561650 | Biomed Pharmacother | The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. | 2021 | Details |
| A04668 | 33546191 | Biomedicines | Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. | 2021 | Details |
| A05786 | 33117316 | Front Microbiol | Microbial Metabolites: Critical Regulators in NAFLD. | 2020 | Details |
| A06116 | 32999906 | GE Port J Gastroenterol | Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. | 2020 | Details |
| A06474 | 32865911 | Crit Rev Oncog | Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression. | 2020 | Details |
| A06558 | 32825440 | Int J Mol Sci | Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. | 2020 | Details |
| A06590 | 32816619 | Gut Microbes | Modifying macronutrients is superior to microbiome transplantation in treating nonalcoholic fatty liver disease. | 2020 | Details |
| A06740 | 32764281 | Nutrients | The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. | 2020 | Details |
| A06936 | 32694178 | Gut | Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. | 2020 | Details |
| A07112 | 32618656 | Am J Gastroenterol | Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. | 2020 | Details |
| A07681 | 32392712 | J Clin Med | A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. | 2020 | Details |
| A07686 | 32390701 | World J Gastroenterol | Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. | 2020 | Details |
| A07697 | 32388250 | J Nutr Biochem | Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. | 2020 | Details |
| A08601 | 32044317 | Gastroenterology | Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? | 2020 | Details |
| A08694 | 32020359 | Dig Dis Sci | Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. | 2020 | Details |
| A08832 | 31973214 | Nutrients | Murine Genetic Background Overcomes Gut Microbiota Changes to Explain Metabolic Response to High-Fat Diet. | 2020 | Details |
| A09184 | 31845054 | J Gastroenterol | Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. | 2019 | Details |
| A09227 | 31828683 | Eur J Clin Microbiol Infect Dis | Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. | 2019 | Details |
| A09757 | 31622696 | J Hepatol | The gut-liver axis in liver disease: Pathophysiological basis for therapy. | 2019 | Details |
| A09814 | 31600750 | Digestion | Rodent Models of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09960 | 31543403 | Cell Metab | Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. | 2019 | Details |
| A10233 | 31419514 | J Hepatol | Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. | 2019 | Details |
| A10364 | 31373710 | Aliment Pharmacol Ther | Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. | 2019 | Details |
| A10373 | 31367159 | World J Gastroenterol | Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis via gut microbiota. | 2019 | Details |
| A10451 | 31332389 | Nat Med | Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. | 2019 | Details |
| A10919 | 31124558 | Am J Clin Nutr | Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. | 2019 | Details |
| A11579 | 30832423 | Microorganisms | Microbial Population Changes and Their Relationship with Human Health and Disease. | 2019 | Details |
| A11686 | 30791767 | Expert Rev Gastroenterol Hepatol | Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. | 2019 | Details |
| A11922 | 30680920 | Mol Nutr Food Res | Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice. | 2019 | Details |
| A12061 | 30618824 | Front Physiol | Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. | 2018 | Details |
| A12159 | 30578461 | Adv Exp Med Biol | Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT). | 2019 | Details |
| A13021 | 30178233 | Front Med | Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. | 2018 | Details |
| A13029 | 30173562 | Expert Opin Biol Ther | Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. | 2018 | Details |
| A13509 | 29942096 | Nat Med | Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. | 2018 | Details |
| A13680 | 29843959 | Trends Immunol | Liver-Microbiome Axis in Health and Disease. | 2018 | Details |
| A13717 | 29793999 | Diabetes | The Transplantation of ω3 PUFA-Altered Gut Microbiota of fat-1 Mice to Wild-Type Littermates Prevents Obesity and Associated Metabolic Disorders. | 2018 | Details |
| A15065 | 29113028 | Hepatology | Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. | 2018 | Details |
| A15130 | 29083037 | Aliment Pharmacol Ther | Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. | 2017 | Details |
| A15273 | 28990516 | Curr Med Chem | Gut Microbiota as a Therapeutic Target for Metabolic Disorders. | 2018 | Details |
| A15565 | 28840809 | Microbiol Spectr | Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. | 2017 | Details |
| A16017 | 28609252 | Gut Microbes | Fecal microbiota transplantation in metabolic syndrome: History, present and future. | 2017 | Details |
| A16125 | 28550391 | Hepatol Int | Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. | 2017 | Details |
| A16247 | 28484247 | Sci Rep | Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. | 2017 | Details |
| A16342 | 28446519 | Diabetes | Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis, Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia. | 2017 | Details |
| A16455 | 28376573 | Aust Fam Physician | The gut microbiome. | 2017 | Details |
| A16838 | 28134687 | Curr Opin Gastroenterol | Fecal microbiota transplantation for gastrointestinal disorders. | 2017 | Details |
| A18581 | 27048904 | Best Pract Res Clin Gastroenterol | Intestinal microbiota in liver disease. | 2016 | Details |
| A20222 | 26078557 | World J Gastroenterol | What are the effects of proton pump inhibitors on the small intestine? | 2015 | Details |
| A21079 | 25548472 | World J Gastroenterol | Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective. | 2014 | Details |
| A23131 | 24018052 | Gastroenterology | Therapeutic potential of fecal microbiota transplantation. | 2013 | Details |
| A42308 | 34912328 | Front Immunol | Fecal Microbiota Transplantation Controls Progression of Experimental Autoimmune Hepatitis in Mice by Modulating the TFR/TFH Immune Imbalance and Intestinal Microbiota Composition. | 2021 | Details |
| A42511 | 34328191 | Int J Mol Med | Dysbiosis and liver diseases (Review). | 2021 | Details |
| A42596 | 34074837 | Am J Gastroenterol | Response to Ianiro et al. | 2021 | Details |
| A42597 | 34074836 | Am J Gastroenterol | Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better? | 2021 | Details |
| A43181 | 32356701 | Med Sci (Paris) | [Intestinal bacteria involved in nutritional liver disease killed by phagotherapy: a new therapeutic target]. | 2020 | Details |
| A43503 | 31573550 | J Clin Invest | The gut microbiome and metabolic syndrome. | 2019 | Details |
| A44341 | 28914862 | Ter Arkh | [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. | 2017 | Details |
| A47004 | 30643227 | Nat Rev Gastroenterol Hepatol | Alcohol, liver disease and the gut microbiota. | 2019 | Details |
| A47710 | 33163830 | Hepatol Commun | Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. | 2020 | Details |
| A47824 | 31301451 | Clin Gastroenterol Hepatol | Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. | 2019 | Details |
| A48754 | 29687200 | Probiotics Antimicrob Proteins | Are Probiotics Effective in Targeting Alcoholic Liver Diseases? | 2019 | Details |
| A48785 | 28770495 | Curr Infect Dis Rep | Fecal Microbiota Transplantation: Beyond Clostridium difficile. | 2017 | Details |
| A49755 | 35646285 | World J Gastrointest Oncol | Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. | 2022 | Details |
| A50157 | 35500802 | J Ethnopharmacol | Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. | 2022 | Details |
| A50787 | 35266816 | mBio | Interleukin-17 Weakens the NAFLD/NASH Process by Facilitating Intestinal Barrier Restoration Depending on the Gut Microbiota. | 2022 | Details |
| A51737 | 34460287 | Infect Immun | The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. | 2021 | Details |
| A51840 | 33785557 | Gut | Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. | 2021 | Details |
| A52302 | 28892150 | J Pathol | Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. | 2017 | Details |
| A52496 | 26348073 | J Physiol Pharmacol | Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. | 2015 | Details |